A synthetic combinatorial approach to disabling deviant Hedgehog signaling

C. W. Fan, N. Yarravarapu, H. Shi, O. Kulak, J. Kim, C. Chen, L. Lum

Research output: Contribution to journalArticle

Abstract

Mutations in components of the Hedgehog (HH) signal transduction pathway are found in the majority of basal cell carcinoma (BCC) and medulloblastoma incidents. Cancerous cells with intrinsic or acquired resistance to antagonists targeting the seven transmembrane effector Smoothened (SMO) frequently invoke alternative mechanisms for maintaining deviant activity of the GLI DNA binding proteins. Here we introduce a chemical agent that simultaneously achieves inhibition of SMO and GLI activity by direct targeting of the SMO heptahelical domain and the GLI-modifying enzymes belonging to the histone deacetylase (HDAC) family. We demonstrate a small molecule SMO-HDAC antagonist (IHR-SAHA) retains inhibitory activity for GLI transcription induced by SMO-dependent and -independent mechanisms frequently associated with cancer biogenesis. Synthetic combinatorial therapeutic agents such as IHR-SAHA that a priori disable cancer drivers and anticipated mechanisms of drug resistance could extend the duration of disease remission, and provide an alternative clinical development path for realizing combinatorial therapy modalities.

Original languageEnglish (US)
Article number1133
JournalScientific Reports
Volume8
Issue number1
DOIs
StatePublished - Dec 1 2018

Fingerprint

Histone Deacetylases
Medulloblastoma
Critical Pathways
Basal Cell Carcinoma
DNA-Binding Proteins
Drug Resistance
Signal Transduction
Neoplasms
Mutation
Enzymes
Therapeutics

ASJC Scopus subject areas

  • General

Cite this

A synthetic combinatorial approach to disabling deviant Hedgehog signaling. / Fan, C. W.; Yarravarapu, N.; Shi, H.; Kulak, O.; Kim, J.; Chen, C.; Lum, L.

In: Scientific Reports, Vol. 8, No. 1, 1133, 01.12.2018.

Research output: Contribution to journalArticle

Fan, C. W. ; Yarravarapu, N. ; Shi, H. ; Kulak, O. ; Kim, J. ; Chen, C. ; Lum, L. / A synthetic combinatorial approach to disabling deviant Hedgehog signaling. In: Scientific Reports. 2018 ; Vol. 8, No. 1.
@article{474073ee21db425fb2faea4e6c685222,
title = "A synthetic combinatorial approach to disabling deviant Hedgehog signaling",
abstract = "Mutations in components of the Hedgehog (HH) signal transduction pathway are found in the majority of basal cell carcinoma (BCC) and medulloblastoma incidents. Cancerous cells with intrinsic or acquired resistance to antagonists targeting the seven transmembrane effector Smoothened (SMO) frequently invoke alternative mechanisms for maintaining deviant activity of the GLI DNA binding proteins. Here we introduce a chemical agent that simultaneously achieves inhibition of SMO and GLI activity by direct targeting of the SMO heptahelical domain and the GLI-modifying enzymes belonging to the histone deacetylase (HDAC) family. We demonstrate a small molecule SMO-HDAC antagonist (IHR-SAHA) retains inhibitory activity for GLI transcription induced by SMO-dependent and -independent mechanisms frequently associated with cancer biogenesis. Synthetic combinatorial therapeutic agents such as IHR-SAHA that a priori disable cancer drivers and anticipated mechanisms of drug resistance could extend the duration of disease remission, and provide an alternative clinical development path for realizing combinatorial therapy modalities.",
author = "Fan, {C. W.} and N. Yarravarapu and H. Shi and O. Kulak and J. Kim and C. Chen and L. Lum",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41598-018-19408-9",
language = "English (US)",
volume = "8",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - A synthetic combinatorial approach to disabling deviant Hedgehog signaling

AU - Fan, C. W.

AU - Yarravarapu, N.

AU - Shi, H.

AU - Kulak, O.

AU - Kim, J.

AU - Chen, C.

AU - Lum, L.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Mutations in components of the Hedgehog (HH) signal transduction pathway are found in the majority of basal cell carcinoma (BCC) and medulloblastoma incidents. Cancerous cells with intrinsic or acquired resistance to antagonists targeting the seven transmembrane effector Smoothened (SMO) frequently invoke alternative mechanisms for maintaining deviant activity of the GLI DNA binding proteins. Here we introduce a chemical agent that simultaneously achieves inhibition of SMO and GLI activity by direct targeting of the SMO heptahelical domain and the GLI-modifying enzymes belonging to the histone deacetylase (HDAC) family. We demonstrate a small molecule SMO-HDAC antagonist (IHR-SAHA) retains inhibitory activity for GLI transcription induced by SMO-dependent and -independent mechanisms frequently associated with cancer biogenesis. Synthetic combinatorial therapeutic agents such as IHR-SAHA that a priori disable cancer drivers and anticipated mechanisms of drug resistance could extend the duration of disease remission, and provide an alternative clinical development path for realizing combinatorial therapy modalities.

AB - Mutations in components of the Hedgehog (HH) signal transduction pathway are found in the majority of basal cell carcinoma (BCC) and medulloblastoma incidents. Cancerous cells with intrinsic or acquired resistance to antagonists targeting the seven transmembrane effector Smoothened (SMO) frequently invoke alternative mechanisms for maintaining deviant activity of the GLI DNA binding proteins. Here we introduce a chemical agent that simultaneously achieves inhibition of SMO and GLI activity by direct targeting of the SMO heptahelical domain and the GLI-modifying enzymes belonging to the histone deacetylase (HDAC) family. We demonstrate a small molecule SMO-HDAC antagonist (IHR-SAHA) retains inhibitory activity for GLI transcription induced by SMO-dependent and -independent mechanisms frequently associated with cancer biogenesis. Synthetic combinatorial therapeutic agents such as IHR-SAHA that a priori disable cancer drivers and anticipated mechanisms of drug resistance could extend the duration of disease remission, and provide an alternative clinical development path for realizing combinatorial therapy modalities.

UR - http://www.scopus.com/inward/record.url?scp=85040768651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040768651&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-19408-9

DO - 10.1038/s41598-018-19408-9

M3 - Article

C2 - 29348431

AN - SCOPUS:85040768651

VL - 8

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 1133

ER -